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Objective: To ensure accurate and appropriate reporting of non‐invasive prenatal
testing (NIPT) results, the standard of testing should be measured and monitored
by participation in external quality assessment (EQA) schemes. The findings from
international pilot EQAs for NIPT for the common trisomies are presented.
Methods: In the first pilot, three EQA providers used artificially manufactured ref-
erence materials to deliver an EQA for NIPT. The second pilot used clinically collected
maternal plasma samples. The testing and reporting for aneuploidy status was per-
formed by participating laboratories using routine procedures. Reports were assessed
against peer ratified criteria and EQA scores were returned to participants.
Results: Forty laboratories participated in the first. Genotyping accuracy was high;
four laboratories reported a critical genotyping error (10%) and two reported partial
results. Eighty seven laboratories participated in the second pilot using maternal plasma,
two reporting a critical genotyping error (2.3%). For both rounds, report contentwas var-
iable with key information frequently omitted or difficult to identify within the report.
Conclusions: We have successfully delivered an international pilot EQA for NIPT.
When compared with currently available manufactured materials, EQA for NIPT
was best performed using clinically collected maternal plasma. Work is required to
define and improve the standard of reporting.1 | INTRODUCTION
Non‐invasive prenatal testing (NIPT) based on analysis of cell free DNA
(cfDNA) in maternal plasma is now recognised as being a highly- - - - - - - - - - - - - - - - - - - - - - - - - -
the Creative Commons Attributio
d, the use is non‐commercial and
by John Wiley & Sons Ltd.sensitive screening test for trisomies 13,18, and 21. It has been imple-
mented rapidly across the globe.1 NIPT can be delivered using a variety
ofmethodologies but is generally reported to have high sensitivities and
specificities regardless of the platform and methodologies used.2,3- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
n‐NonCommercial‐NoDerivs License, which permits use and distribution in any
no modifications or adaptations are made.
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What is already known about this
topic?
• To ensure laboratories deliver accurate, appropriate, and
effective reporting of tests performed in their
laboratories participation in external quality assessment
(EQA) schemes is required by accrediting bodies.
• There is no international EQA scheme available for NIPT
for aneuploidy.
What does this study add?
• EQA for the common trisomies can be successfully
delivered across multiple laboratories worldwide.
• The EQA is best delivered using clinically collected
maternal plasma samples which can be transported at
room temperature.
• Reporting standards are very variable with key
information often omitted.
• Further work is required to develop internationally
acceptable EQA for NIPT aneuploidy including reporting
standards.
• The high level of participation in these pilots suggests the
need for continued delivery of EQA.
2 DEANS ET AL.There are however many factors that might influence results including
relatively low fetal fractionwith themajority of circulating cfDNA being
maternal in origin,4 although fetal levels increase with gestation and
vary with maternal weight,5-8 placental size, some pregnancy complica-
tions, and multiple pregnancies. In addition, as the majority of cfDNA in
maternal plasma is maternal in origin and the fetal component derives
from the placenta,8 maternal abnormalities and abnormalities confined
to the placenta may be reflected in the results.9 Testing is largely deliv-
ered by commercial providers, either through their own laboratories or
though transferring their technology to both public and private sector
laboratories, although there has been some local development of test-
ing.10,11 There has, however, been very little by way of standardisation.
Indeed, a recent review that included international opinions demon-
strated considerable variation in reporting NIPT results and recom-
mended development and participation in quality assurance schemes.12
To ensure high standards of testing and reporting, it is generally
accepted that it should be delivered by laboratories that are
“accredited.” Internationally, the standard required is defined by
ISO15189.13 External quality assessment (EQA), or proficiency testing
(PT), provides a mechanism by which the clinical, analytical, and inter-
pretation performance of genetic testing centres can be externally
assessed against international standards and compared with other lab-
oratories. To achieve and maintain accreditation for testing, participa-
tion in EQA(s) for all diagnostic services offered is required, and EQA
performance is utilised by national accreditation bodies as a tangible
measure of the quality of a laboratory's performance. Participation in
EQA provides evidence of the standard of testing and reporting
(including accuracy, reliability, and appropriateness), benchmarks the
service against other laboratories providing comparable testing and
is usually undertaken at least annually for every aspect of the diagnos-
tic service. If a centre fails to meet the required standard (based on
best practice guidelines) to pass the individual EQA distribution, the
performance is designated poor, enabling the laboratory to investigate
and perform a root cause analysis to rectify the problem.
EQAs are designed to check and sometimes challenge laboratory
screening and/or testing for a particular genetic disease/disorder or
gene/target combination. Ideally, EQA will cover all aspects of the
diagnostic process through the distribution of the relevant clinical
samples and associated clinical scenarios, ie, the pre‐analytical, analyt-
ical, and post analytical phases (including the clinical interpretation of
results). EQA in genetics is generally qualitative (detecting the pres-
ence or absence of a variant) and the EQAs discussed here are an
example of where such a qualitative approach is used. EQA should
be autonomous from professional and national bodies so independent
external verification of the quality of service is provided as well as giv-
ing confidence to the laboratory, host institution, and users of the ser-
vice that the laboratory's performance is satisfactory.13 There are two
main genetics EQA providers in Europe offering an international ser-
vice: genomic quality assessment (GenQA) (https://www.genqa.org/),
and the european molecular quality network (EMQN) (https://www.
emqn.org/). GenQA offers a wide repertoire of cytogenomic, genomic
and clinical genetics EQAs, and EMQN, which is independent of
GenQA, offers a wide range of genomic EQAs.There are a number of unique challenges in delivering an EQA for
NIPT, mainly providing EQA material for both (a) a variety of assay
platforms and (b) a potentially large number of participants. The major
challenge is to provide sufficient material that is of a suitable quality
and has the relevant genetic aberration. The ideal EQA programme
would provide every EQA participant with a batch of material that is
identical to the sample type they normally receive for routine testing
(ie, the same material type provided in the same quantity, collected,
stored, and transported in the optimal manner). To allow inter‐
laboratory comparison, the material provided should ideally come from
a single or small number of batches, the genotype of which has been
independently validated by at least two different laboratories, prior
to provision of the EQA. The EQA provider also needs to ensure that
the samples have not deteriorated in the interval between validation
and testing by the participant laboratories and to also consider the
cost of sourcing the materials and transportation requirements. Whilst
real clinical samples are ideally used for EQA, in some circumstances,
artificial material may be appropriate to meet these requirements.
Themain advantage of artificial referencematerials is that large quan-
tities can be manufactured and validated prior to distribution. Secondly,
these samples are stable at ambient temperature, and consequently, han-
dling and shipping problems/costs can be reduced. Thirdly, a single batch
of material reduces problems associated with sample heterogeneity,
resulting in more reliable inter‐laboratory comparisons. Finally, the use
DEANS ET AL. 3of artificial materials allows for the engineering of specific characteristics
of interest into the sample. For example, in a Chinese NIPT EQA, the
effect of low fetal fraction was investigated by limiting the amount of
sheared fetal DNA in the serum.14 However, there are some disadvan-
tages when using artificial materials as they are not identical to real sam-
ples and consequently their performance in an assay might differ,
potentially leading to a suboptimal assessment. For example, with NIPT,
mechanical shearing of DNA produces fragments which differ in size dis-
tribution from those found in maternal serum, with less small DNA frag-
ments (less than 100 bp) present.14 The fragments produced by
mechanical shearing may also be problematic for paired‐end next gener-
ation sequencing (NGS) approaches. In addition, all commercially avail-
able reference materials are not currently matched for the parent/child
relationship and therefore NIPT platforms using single nucleotide poly-
morphism (SNP) analysis is not possible using these materials.
Real clinical materials have known performance characteristics and
can be tested using all clinically relevant methodologies therefore rep-
resent the gold standard. However, many laboratories require up to
4 ml of plasma to complete NIPT testing thus it is not possible to
obtain sufficient amounts of donated plasma from a single pregnant
patient required for a large EQA programme. Any EQA for NIPT will
therefore need to use multiple samples/sources for the sample distri-
bution, which limits the reliability of inter‐laboratory comparison.
Additionally, any validation requirements reduce the volume of sample
available for participants to test. In addition, as handling, transit
time/conditions, and freeze/thawing are all factors that affect the rel-
ative proportions of maternal and fetal DNA in plasma,15 careful con-
sideration is required to ensure the EQA samples arrive in an optimal
condition. In order to guarantee stability of real samples, it may be
necessary to consider low temperature distribution on dry ice thereby
increasing the costs and logistical difficulties of exporting the EQA
materials. Finally, the restrictive availability of material from pregnan-
cies with the rarer trisomies, eg, Edwards and Patau syndromes, are
an additional limiting factor which makes offering a comprehensive
range of different NIPT EQA samples a challenge.
To inform the development of an international EQA scheme, we
describe two pilot EQA rounds for NIPT in singleton pregnancies deliv-
ered by the two main genetics EQA providers, GenQA and EMQN. The
first uses artificial materials and the second real clinical materials.2 | METHODS
2.1 | EQA pilot 1
A commercial reference material provider, SeraCare, was commissioned
to manufacture bespoke artificial materials for use in the first EQA pilot.
Specific details of manufacture are held by the manufacturer who work
to the relevant ISO standards.13 All samples were independently vali-
dated by the EQA providers before distribution. One sample contained
cfDNA with trisomy 21 at a fetal fraction of 4%, the second sample
contained cfDNAwith trisomy 18 at a fetal fraction of 10%, and the final
sample was low risk of trisomy 13, 18, and 21, with a cell free fetalfraction of 12%.DNA at a concentration of 20 ng/mL, sheared to approx-
imately 170 base pairs in size, was supplied in 1 mL aliquots of human
plasma. Participating laboratories were requested to assume that the
plasma has been double spun prior to receipt. If laboratories required
more than 1 mL of plasma for processing, then they were instructed to
dilute the sample with buffer to the required volume for testing.
The expected results were confirmed prior to EQA distribution by
independently validating the samples in four laboratories using different
testing protocols. The known limitation of the EQA material was that the
maternal and placentally‐derived cfDNA was not matched and thus labo-
ratories using methods reliant on comparison between maternal and fetal
SNPs or pair‐ended NGS were not eligible to participate. The validating
laboratories reported the expected genotypes but commented that the
“samples did not perform as well as routine clinical samples.” In order to
meet the overwhelming demand for external quality assessment of NIPT,
it was decided to proceed with the pilot EQA despite these limitations
but without scoring of results or applying performance monitoring.
Each EQA sample was assigned an “EQA patient” name, sample iden-
tifier, reason for referral, and a clinical case scenario (seeTable 1). Partic-
ipants were informed that all samples supplied were from singleton
pregnancies and NIPT for trisomy 13, 18, and 21 was requested. Labora-
tories were asked to analyse samples and report results using their local
standard operating procedures. These reports were submitted electroni-
cally to the EQA provider websites and assessed for genotyping accuracy
anonymously by a panel of NIPT experts. Assessor feedback on the
genotyping and interpretation of the results, as well as the clerical accu-
racy of reports was provided, measured against peer ratified criteria
when required (Table 2), and an individual laboratory report returned to
each laboratory. An incorrect genotype was classified as a critical error.2.2 | EQA pilot 2
Each participating laboratory received two real patient samples (one low‐
risk and one high‐risk for trisomy 21), supplied as 4 mL samples obtained
from approximately 4000 aliquots derived from 86 real maternal plasma
samples, with confirmed pregnancy outcomes (low/high‐risk for common
aneuploidy) obtained from the UK National Institute for Health Research
Reliable Accurate Prenatal non‐Invasive Diagnosis (RAPID) programme
sample biobank.16 These samples were derived from maternal blood col-
lected at the time of invasive testing for clinical indications. Blood was
either collected into Streck tubes, before double‐spinning and plasma sep-
aration, or into EDTA tubes and spunwithin 6 hours of blood draw. Plasma
was aliquoted into 2 mL tubes and stored at −80°C. The frozen samples
were transferred to GenQA and then aliquoted and distributed at ambient
temperature. The sampleswere not pooled and no prior validationwas per-
formed because outcomewas confirmed for all cases. There was sufficient
plasma available for all cases except one to distribute to at least two labo-
ratories. Clinical case scenarios were supplied as outlined for round 1
(Table 1), laboratories were asked to report findings using their standard
format and the submitted reports were assessed as described above for
round 1 except that a score (out of 2.00) was attributed for each marking





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4 DEANS ET AL.
TABLE 2 Marking criteria applied to reports submitted in these EQAs
EQA Round 1
Category Criteria Marks*Case
1 Genotyping No evidence of trisomy 13, 18, and 21 2.0 marks
2 Genotyping Evidence of trisomy 21. No evidence of trisomy 13 and 18. 2.0 marks
3 Genotyping Evidence of trisomy 18. No evidence of trisomy 13 and 21. 2.0 marks
EQA Round 2
1 Genotyping No evidence of trisomy 13, 18, or 21* 2.0 marks
Interpretation Low risk for trisomy 13, 18, and 21 2.0 marks
2 Genotyping Evidence of trisomy 21. No evidence of trisomy 13 or 18* 2.0 marks
Interpretation High risk for trisomy 21. Low risk for trisomy 13 and 18. 2.0 marks
The high‐risk result must be confirmed by invasive prenatal diagnosis
Essential elements within report
Interpretation—deduction of 0.5 marks if omitted applied in Round 2: Clerical accuracy—deduction of 0.5 marks if omitted applied in Round 2:
• Clear clinical interpretation provided • Unique patient identifiers should be given (mother's name, mother's date of birth)
• The testing methodology should be given
• Full limitations of the test should be given • Gestational age at time of sampling
• Date of sample collection
• Date of receipt of sample
• Correct sample type
• Reason for referral
• Report date
Comments
• The use of “positive/negative” or “abnormal/normal” is not recommended as can be misinterpreted
*The maximum score for each category is 2.0 marks. Deductions are made for missing essential elements. If an incorrect genotype is reported then this is
classed as a critical genotyping error and 2 marks were deducted.
FIGURE 1 Summary of the mean scores obtained by the participants
in the second pilot for Case 1 and Case 2. Maximum mean score
obtainable is 2.0
DEANS ET AL. 53 | RESULTS
3.1 | EQA pilot 1
Forty five laboratories from 19 different countries in five continents
registered to participate, and 40 submitted EQA returns within the
allotted reporting period. Four participants failed to submit reports
but did not provide a reason and there was one duplicate registration
(between two EQA providers), which was subsequently reassigned.
Overall, the standard of genotyping accuracy was high. Four labo-
ratories (10%) reported critical genotyping errors; two laboratories
reported the low risk for trisomy 13, 18, and 21, sample to be trisomy
21; and two different laboratories did not report the correct result for
the high‐risk trisomy 21 sample (one reported the case as normal and
the second reported a borderline trisomy 13 result, as well as trisomy
21). Two laboratories reported partial results for one case each, ie, no
conclusive result for one of the chromosomes tested. The EQA pro-
viders did not assign scores for that case to that laboratory, as reason
for the failure to obtain a reportable result could not be determined.
The overall sample failure rate was 18%.
The fetal fraction was reported by 51% of participants, whilst a fur-
ther 40% did not state on the report either the fraction or whether it
had been determined. The remaining 9% participants either reported
the fetal fraction only for the “no abnormality detected” case, or onlycommented when it was not sufficient to meet their internal quality
control standards.3.2 | EQA pilot 2
Ninety six laboratories from 30 different countries registered to par-
ticipate and 86 (89.6%) submitted EQA returns for all cases within
the allotted reporting period. Nine participants failed to submit reports
for either case but did not provide a reason. One laboratory submitted
FIGURE 2 Summary of the range of total
scores obtained by the participants in the
second pilot. Maximum score obtainable is 12
6 DEANS ET AL.results for Case 1 only, and three laboratories reported test failures for
one or both cases.
The standard of genotyping was higher than in the first EQA, with
only two laboratories (2.3%) making a critical genotyping error: one
laboratory incorrectly reported the low‐risk case (Case 1) as high‐risk
for trisomy 13, and another one incorrectly reported Case 2 as high‐
risk for trisomy 18 and low‐risk for 13 and 21. As multiple samples
were distributed for each case, then no assessment of fetal fraction
was performed. Figure 1 summarises the mean scores obtained byFIGURE 3 Description of the methodologies tested in pilot 2 as
described by participants in their reports showing the wide variation
in terminology used, some generic and some using brand names
FIGURE 4 Summary of risk figures provided by laboratories in the seconall participating laboratories and Figure 2 summarises the range of
scores obtained. There was a wide range of ways to describe the
methods used (Figure 3), and several reports contained insufficient
information on the limitations of the test performed. Assessors based
their evaluation of reports on the international consensus reached
previously,12 which is in line with many national recommendations
(Table 2).
Risk figures were provided in 27% and 34% of reports for Case 1
(low‐risk case) and case 2 (low‐risk trisomy 13 and 18, high‐risk tri-
somy 21 case), respectively (Figure 4). Laboratories which provided a
risk figure reported the results using a range of different terminologies
(Figure 5).
Three laboratories were unable to obtain a result from the material
provided; one did not obtain results for either cases, a second did not
obtain a reportable result for Case 1 and a third did not report results
for Case 2. All remaining laboratories submitted a result for both cases
and the overall sample failure rate in this EQA pilot was 2.3%.3.3 | Report format for both pilot EQA rounds
The format of the reports was very variable for both pilot EQA rounds
with essential information missing from the main body of the text,
making it difficult to find. Many reports embedded essential informa-
tion (eg, the requirement to confirm the high‐risk result by invasive
testing) either in the footer, a rider, or just generally in a nonprominentd pilot; low‐risk case (hatched) and high‐risk case (block)
FIGURE 5 Summary of the terminology used to report the results in the second pilot for (A) the low risk case and (B) the case that was low risk
for trisomy 13 and 18, high risk trisomy 21
DEANS ET AL. 7position on the report. In some reports submitted for Case 2, only the
high‐risk result was stated and the results for other chromosomes
tested was omitted. It is generally accepted that clinical reports should
include all results.17 Conversely, other laboratories reported the results
of “extra extended testing,”which had not been requested. One labora-
tory reported results for other conditions/abnormalities and nine labo-
ratories reported the fetal sex. Several laboratories used terms such as
“positive/negative” or “abnormal/normal” in their reports, the meaning
of which could be easily misinterpreted (Figure 5). In Case 2, where the
results indicated high risk for trisomy 21, reports often contained a
generic comment about additional testing without specifying that inva-
sive prenatal testing is required for confirmation of the result. A number
of laboratories appeared to outsource their NIPT to another provider,
but none of their submitted reports stated this, although this is a man-
datory requirement of ISO 15189.13
Although the majority of laboratories provided details of the test
performed, there was considerable variation in the type of information
provided (Table 2). Information on the bioinformatic work‐up was not
given in the majority of reports, and laboratories that were using a com-
mercial test did not describe the methodology of the assay or give a ref-
erence to inform the reader where the information could be accessed.4 | DISCUSSION
We have successfully demonstrated that EQA can be delivered to lab-
oratories performing NIPT for the three common trisomies based on
analysis of cfDNA in maternal plasma. The first used artificially created
materials which were not applicable to all laboratories and had a
higher failure rate than the second, which used real maternal plasma
samples applicable to all providers and with a low critical error rate
(2.3%). As these are pilot exercises, no official performance monitoring
was applied although the EQA providers notified the laboratories of
any suboptimal performance and offered help and support to identify
and correct the root cause. As the plasma was sent at ambient temper-
ature to 30 different countries in Asia, Australasia, Europe, and North
America and the failures were not correlated with an extended time in
transit, we have shown the stability of the maternal plasma, allowing
future EQA rounds to send the samples globally without risk of signif-
icant degradation.
The EQAhas also shown considerable variation in the content of the
reports, with many containing insufficient information such that the cli-
nician reading them could misinterpret the results or be unaware of the
nature and/or limitations of the NIPT screening test. This highlights the
8 DEANS ET AL.need for more standardisation and EQA in this field. For these EQAs, we
based the standard on the consensus on report content that has
recently been published to evaluate results,12 but these should be
reviewed and endorsed EQA providers internationally before further
evaluation.
In addition to essential elements required in an NIPT report such as
method(s) used, whether targeted or whole genome sequencing, to
indicate the extent of testing fetal fraction is another important param-
eter that may be included in a report. However, there is considerable
variation in the way the testing methodology was described, and some
providers using a defined fetal fraction as a cut‐off to fail results; others
using it as a quality measure and others not commenting at all. There is
also variability in the accuracy of fetal fractionmeasurement and debate
as towhether or not this should be included in the report. AmericanCol-
lege of Medical Genetics and Genomics (ACMG) guidelines18 state that
fetal fraction measurement is essential for accurate interpretation of
the results and that it should be displayed on the report, whilst an Inter-
national Society for Peritoneal Dialysis (ISPD) workshop publication
reporting consensus opinion for recommended practice showed lack
of consensus as to whether or not fetal fraction should be measured
or reported.12 This is clearly an area for further discussion as the EQA
parameters are refined.
The results should state whether it is a high risk or low risk with
results given for all chromosomes tested. As this is a screening test,
it is essential that the reader of the report is aware there can be
false‐negative and false‐positive results, and the report should state
clearly that all high‐risk results should be confirmed by invasive diag-
nostic testing. The most frequent omission was not stating the limita-
tions of the test performed, which included (a) the sensitivity and
specificity of the test, (b) a statement that the NIPT aneuploidy does
not cover other genetic abnormalities, and (c) stating the risk of
false‐positive or false‐negative results. Discrepant results can be
caused by either technical or biological factors such as very low fetal
fraction, confined placental mosaicism (CPM), maternal copy number
variation, or a vanishing twin.8,19
It is important that there is no ambiguity in the language when
describing the results. A third of laboratories stated the result was either
high or low risk whilst two‐thirds provided some estimation of this risk.
Some centres gave a precise risk calculation but this figure was not
always consistent with the sensitivity of the assay. Overall, there was
considerable variation in the risk calculation provided by laboratories
regardless of whether it was a high or low risk result. Given the disparity
seen and recent debate from lay support groups, further discussion on
the terminology used is required, but terms “high‐risk” and “low risk”
or “high chance” or “low chance” rather than “normal/abnormal” or
“positive/negative” are likely to be more acceptable. The adoption of
these terms by laboratories will need to be assessed in future EQA
distributions.
Since delivering these pilot EQAs, an improved artificial reference
sample has been developed that allows pairing of the maternal and fetal
genotypes. This means that it is potentially usable on all platforms cur-
rently available. As sourcing clinical samples for large NIPT EQAs is
going to be challenging, access to suitable manufactured materials hassignificant potential advantages.We therefore plan a further pilot EQAs
which will distribute both real plasma samples and artificial samples to
allow comparison and inclusion of all testing laboratories.
In conclusion, two pilot EQAs for NIPT for aneuploidy in singleton
pregnancies have been successfully run and shown that using maternal
plasma samples shipped at ambient temperature is superior and more
widely applicable. However, there are practical issues that need to be
addressed before initiating a formal EQA over a wider range of labora-
tories, including how to source sufficient plasma samples in the future
and terminology to be used in reporting. The significant variation in
reporting standards will need to be addressed in future EQAs and fur-
ther discussion is required to harmonise the approach across the globe,
but the data we report here has highlighted the issues that need to be
addressed in future EQAs. Finally, the study reported here describes
piloting EQA in singleton pregnancies, clearly there are other situations
that will require evaluation including multiple pregnancies and those
conceived following assisted conception.
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